Sunshine advances coronavirus drug program
Compartilhar
Sunshine Biopharma (NASDAQ:SBFM) advanced its lead coronavirus PLpro inhibitor into IND-enabling studies after preclinical testing showed antiviral activity against SARS-CoV-2 variants.
Sunshine Biopharma (NASDAQ:SBFM) advanced its lead coronavirus PLpro inhibitor into IND-enabling studies after preclinical testing showed antiviral activity against SARS-CoV-2 variants.
Sunshine Biopharma (NASDAQ:SBFM) received Canadian regulatory approval for its 1mg generic Anastrozole tablets, the equivalent of Arimidex.
Sunshine Biopharma (NASDAQ:SBFM) has filed its Form 10-K for the fiscal year ended December 31, 2025, reporting a steady increase in top-line revenue alongside a significant expansion of its generic drug portfolio.
